This clinical trial is focused on studying the effects of a group of medications called glucocorticoids on a lung disease known as Idiopathic Pulmonary Fibrosis (IPF). IPF is a condition where the lungs become scarred and breathing becomes difficult. The trial will compare the use of glucocorticoids to a placebo in treating sudden worsening of this disease, known as an acute exacerbation. The glucocorticoids being studied include Methylprednisolone, which is given as an injection, and Liquid Prednisone, which is taken by mouth. The purpose of the study is to see if these medications can help reduce the risk of death within 30 days for patients experiencing an acute exacerbation of IPF.

Participants in the study will receive either the glucocorticoid treatment or a placebo. The study will monitor the participants’ health over a period of time, focusing on their survival rate at 30 days. Other aspects of their health will also be observed, such as their lung function, any need for intensive care, and overall well-being. The study aims to gather information on how effective glucocorticoids are in managing the acute worsening of IPF and whether they can improve the outcomes for patients.

Throughout the study, various health parameters will be checked, including blood sugar levels, heart rate, and blood pressure. The study will also look at any changes in the participants’ lung condition and their overall health status. This research hopes to provide valuable insights into the treatment of IPF and potentially improve the quality of life for those affected by this challenging condition.